Sanofi Includes OTCs As Key Touchstone On Growth Chart
This article was originally published in The Tan Sheet
Executive Summary
Sanofi-Aventis' planned dedicated OTC division will be a key component in the firm's efforts to better focus on maximizing product opportunities and identifying new acquisition targets
You may also be interested in...
Sanofi Builds OTC Business Through Organic Growth And Bolt-Ons
Sanofi-Aventis in its latest quarter made headway toward doubling its OTC business by 2014, reporting 7.4 percent organic growth and 26.3 percent growth including acquisitions in the segment
Sanofi Builds OTC Business Through Organic Growth And Bolt-Ons
Sanofi-Aventis in its latest quarter made headway toward doubling its OTC business by 2014, reporting 7.4 percent organic growth and 26.3 percent growth including acquisitions in the segment
Sanofi Builds OTC Business Through Organic Growth And Bolt-Ons
Sanofi-Aventis in its latest quarter made headway toward doubling its OTC business by 2014, reporting 7.4 percent organic growth and 26.3 percent growth including acquisitions in the segment